PRESTIGE CONSUMER HEALTHCARE INC. financials

  1. Home
  2. Financials
  3. PBH
PBH CIK 0001295947

Source: EDGAR filings · Built 2026-06-02T03:47:38Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2026FY 2025FY 2024FY 2023FY 2022FY 2021
Free Cash Flow 243.97M 238.75M 236.55M 219.18M 247.70M 211.92M
EBITDA 340.68M 366.95M 373.10M 10.21M 362.01M 327.57M
Working Capital 310.56M 341.70M 258.00M 231.03M 149.84M 147.70M
Net Debt 978.57M 946.37M 1.10B 1.31B 1.48B 1.48B
Gross Margin 54.71% 55.76% 55.49% 55.45% 57.11% 58.03%
Operating Margin 28.42% 29.60% 30.43% -1.99% 30.36% 31.53%
Net Margin 17.48% 18.86% 18.60% -7.30% 18.90% 17.46%
Return on Equity (ROE) 10.08% 11.70% 12.65% -5.69% 13.02% 12.12%
Return on Assets (ROA) 5.45% 6.31% 6.31% -2.45% 5.60% 4.80%
Current Ratio 3.57× 4.20× 3.20× 2.44× 2.04× 2.21×
Debt-to-Equity 0.55× 0.57× 0.69× 0.94× 0.95× 1.12×
Effective Tax Rate 26.10% 24.49% 24.16% 12.36% 21.75% 19.32%
Cash Conversion Ratio 1.35× 1.17× 1.19× -2.79× 1.27× 1.43×
Accruals Ratio -0.02× -0.01× -0.01× -0.09× -0.01× -0.02×
SBC % of Revenue 1.00% 0.98% 1.24% 1.10% 0.83% 0.91%
CapEx Coverage 18.86× 19.71× 20.11× 21.80× 21.26× 9.95×
Free Cash Flow Per Share $5.01 $4.77 $4.71 $4.39 $4.87 $4.19

Valuation Metrics

Concept FY 2026FY 2025FY 2024FY 2023FY 2022FY 2021
P/E Trailing (Diluted) 15.16× 20.04× 17.40× — 13.10× 13.56×
P/FCF 11.84× 18.03× 15.39× 14.26× 10.87× 10.53×
FCF Yield 8.45% 5.55% 6.50% 7.01% 9.20% 9.50%
EV / EBITDA 12.65× 15.70× 13.75× 464.67× 12.05× 11.79×
P/S 3.06× 4.23× 3.58× 3.05× 2.65× 2.52×
P/B 1.77× 2.62× 2.43× 2.37× 1.83× 1.75×

Income Statement

Concept FY 2026FY 2025FY 2024FY 2023FY 2022FY 2021
Revenue from Contract with Customer, Excluding Assessed Tax 1.09B 1.14B 1.13B 1.13B 1.09B 943.37M
Cost of Revenue 493.13M 503.30M 500.91M 502.43M 466.17M 395.89M
Gross Profit 595.58M 634.46M 624.45M 625.29M 620.65M 547.47M
Operating Expenses 286.17M 297.69M 282.02M 647.71M 290.73M 250.07M
Operating Income (Loss) 309.41M 336.77M 342.43M -22.41M 329.92M 297.40M
Income Tax Expense (Benefit) 67.19M 69.58M 66.69M -11.61M 57.08M 39.43M
Net Income (Loss) Attributable to Parent 190.30M 214.60M 209.34M -82.31M 205.38M 164.68M
Earnings Per Share, Basic $3.93 $4.32 $4.21 $-1.65 $4.09 $3.28
Weighted Average Number of Shares Outstanding, Basic 48.46M 49.70M 49.76M 49.89M 50.26M 50.21M
Earnings Per Share, Diluted $3.91 $4.29 $4.17 $-1.65 $4.04 $3.25
Weighted Average Number of Shares Outstanding, Diluted 48.72M 50.08M 50.18M 49.89M 50.84M 50.60M

Balance Sheet

Concept FY 2026FY 2025FY 2024FY 2023FY 2022FY 2021
Cash and Cash Equivalents, at Carrying Value 63.87M 97.88M 46.47M 58.49M 27.18M 32.30M
Assets, Current 431.48M 448.33M 375.04M 391.74M 293.27M 269.83M
Assets 3.49B 3.40B 3.32B 3.35B 3.67B 3.43B
Long-term Debt 993.95M 992.36M 1.13B 1.35B 1.48B 1.48B
Liabilities, Current 120.92M 106.62M 117.05M 160.72M 143.42M 122.14M
Long-term Debt, Excluding Current Maturities — — 1.14B 1.35B 1.48B 1.48B
Liabilities 1.61B 1.57B 1.66B 1.91B 2.09B 2.07B
Stockholders' Equity Attributable to Parent 1.89B 1.83B 1.66B 1.45B 1.58B 1.36B

Cash Flow Statement

Concept FY 2026FY 2025FY 2024FY 2023FY 2022FY 2021
Net Cash Provided by (Used in) Operating Activities 257.63M 251.51M 248.93M 229.72M 259.92M 235.61M
Payments to Acquire Property, Plant, and Equipment 11.18M 8.22M 9.55M 7.78M 9.64M 22.24M
Net Cash Provided by (Used in) Investing Activities -136.84M -17.45M -20.11M -11.58M -256.51M -22.24M
Payments for Repurchase of Common Stock 156.28M 51.51M 25.00M 50.00M 0 11.87M
Net Cash Provided by (Used in) Financing Activities -156.06M -182.07M -241.01M -185.85M -7.57M -279.42M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (PBH CIK 0001295947), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

VTGN

Vistagen Therapeutics, Inc.

DX

DYNEX CAPITAL, INC.

NHC

NATIONAL HEALTHCARE CORP